Arrangement

Oslo Life Science – Perspectives

16. februar 2017

UiO University Aula,Oslo,0162

Day 2: Oslo Life Science – the main conference day with perspectives from academia, businesses and politics.

Oslo Life Science 2017 – Day 2

– Program 16th February 2017

This is the main conference day with perspectives from academia, businesses and politics. There is a reception in the Oslo City Hall in the evening.

Registration from 08.45.

Her Royal Highness Crown Princess Mette-Marit Her Royal Highness Crown Princess Mette-Marit will be present at the opening.

09.30 – Introduction

Nadia Hasnaoui Introduction by Conference Host Nadia Hasnaoui
Ole Petter Ottersen Welcome to the Oslo Life Science Conference

Rector of the University of Oslo, Ole Petter Ottersen

09.45 – Building excellence in science and innovation I

Anne O’Garra Systems approaches to studying the immune response in infection research at the Francis Crick Institute

Associate Research Director (Group Leader Development), the Francis Crick Institute, Anne O’Garra

John-Arne Røttingen New vaccines for a safer world

Interim CEO, Coalition for Epidemic Preparedness Innovations (CEPI), John-Arne Røttingen
Specialist Director, the Norwegian Institute of Public Health, Professor II, Institute of Health and Society, UiO, and Adjunct Professor Harvard T.H.Chan School of Public Health

Kjetil Taskén Future in personalised cancer therapy

Director and Professor, Centre for Molecular Medicine Norway NCMM – Nordic EMBL Partnership University of Oslo (NCMM), Kjetil Taskén

Inger Sandlie To build a culture for innovation

Professor, Department of Biosciences, the University of Oslo and Centre for Immune Regulation, UiO/Oslo University Hospital, Inger Sandlie 

Bjørn Hofmann Looking for health or looking for trouble? Addressing ethical issues to improve innovation

Professor, NTNU Gjøvik and Professor II, Centre for Medical Ethics, University of Oslo, Bjørn Hofmann

Erlend B. Smeland The UiO:Life Science initiative: why is it important for Oslo University Hospital?

Director of research, innovation and education, Oslo University Hospital, Erlend B. Smeland

Building political initiatives for growth in life sciences

Anne Kjersti Fahlvik Moving forward with an ecosystem approach

Executive Director, Division for Innovation, the Research Council of Norway, Anne Kjersti Fahlvik

11.00 Lunch

12.00 Building political initiatives for growth in life sciences continues

Liselotte Højgaard A stronger Danish life science – advice to the government from industry and academia

Member of the growth team for life science appointed by the Danish government, Head of Department at Rigshospitalet and Professor at the University of Copenhagen, Liselotte Højgaard

Bjørn Haugstad The government’s strategies for enabling technologies 

State Secretary, Ministry of Education and Research, Bjørn Haugstad (PhD)

Raymond Johansen Ambitions for green growth in the Life Science City

Governing Mayor, the City of Oslo, Raymond Johansen

TBD Implementation of the Health&Care21 strategy

Speaker TBD

Building convergence in research and education

Salehi-Reyhani Driving innovation through hackspace environments and cohort based PhD training programmes

Research Fellow, Department of Chemistry, Imperial College London, Ali Salehi-Reyhani (PhD)

 

Torleif Tollefsrud Gjølberg and Ragnhild Bugge Student innovation against antibiotic resistance

Students from the UiO iGEM-team 2016, Torleif Tollefsrud Gjølberg and Ragnhild Bugge

Tone Tønjum Fighting the superbugs – turning the tide of antimicrobial resistance

Head of Unit for Genome Dynamics, Department of Microbiology, Oslo University Hospital, and Professor, Institute of Clinical Medicine, the University of Oslo, Tone Tønjum

Pål Rongved The ZinChel technology – fighting the ticking time-bomb of antimicrobial resistance

Professor, the School of Pharmacy, the University of Oslo, Pål Rongved

 

13.30 Coffee break

14.10 Building excellence in science and innovation II

Remi Eriksen Digitalization, data and life sciences – why is DNV GL involved in BIGMED?

President and CEO, DNV GL, Remi Eriksen

Kerstin Papenfuss MRC Technology and accelerating the discovery and development of novel cancer therapeutics: Keytruda and beyond

Therapeutics Review Team Leader, MRC Technology, UK, Kerstin Papenfuss (PhD)

Laura Chirica Diagnosis of early stages of pancreatic cancer

Chief Commercial Officer, Immunovia, Laura Chirica (PhD)

Guro Lind Developing a urine test for bladder cancer

Head of the Epigentics group, Oslo University Hospital, and Professor II, Department of Biosciences, UiO, Guro Lind

James P. Sullivan Tomorrow’s innovation: Changing R&D model in Life Science

VP, Pharmaceuticals Discovery, AbbVie, James P. Sullivan

15.45 – Closing keynote and closing remarks

Tim Rowe Building effective startup ecosystems

Founder and CEO of CIC (Cambridge Innovation Center), Tim Rowe

Finn-Eirik Johansen

Closing remarks 
Director UiO:Life Science, Professor Finn-Eirik Johansen

16.15 – Finished

18.00–19.30 – Reception Oslo City Hall

Arrangementsinfo

UiO University Aula

Karl Johans gate 47
Oslo, 0162 Norway

16. februar 2017

Kontaktpersoner

Kathrine Kjendlie
LL.B. Juss
I nærmere 20 år jobbet hun med varemerker innen farmasøytisk industri. I dag er fokuset på varemerke- og designrett, registrerbarhetsundersøkelser og overvåkning av rettigheter.
Kari Simonsen
Cand.scient., Biokjemi
Utdannet i biokjemi/bioteknologi med kunnskap innen life science, farmakologi, legemiddelkjemi m.v. I tillegg næringsmiddelområdet, aquakultur m.m. Med ekstra forse i håndhevelse.
Håndterer varemerker, piratkopier og urettferdig konkurranse for multinasjonale selskaper. Tidligere leder for Patentstyrets juridiske avdeling og var deres delegat i WIPO og EPO.

Relaterte artikler

Les mer interessant innhold om temaet.

Skal du opprette varemerke for et registrert legemiddel, er det viktig å vite hvilke 7 krav som stilles for å komme gjennom Statens Legemiddelverks nåløye.
1564
Onsagers’ klient ble hørt på alle punkter da retten sa seg enig i at lilla er det naturlige fargevalget på en astmainhalator, bl.a. av hensyn til pasientsikkerhet.
1838
Kari Simonsen, fra Onsagers’ Farmasi og biotek-bransjeteam, blir intervjuet av Mediaplanet om IP-utfordringer, innovasjonsprosessen og de vanligste kundehenvendelsene.
1809
bolger